Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

Personalised Medicine > PMED in Oncology > Flashcards

PMED in Oncology Flashcards

(62 cards)

Start Studying
1
Q

cancer 101

A

mutated cell
(uncontrolled growth)

primary tumour
(invasion and dissemination via blood and lymphatics)
metastatic tumour

or

treatment - remission
recurrence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what are the molecular aspects of cancer

A

genetic alteration (mutation)

altered protein (mutant form, overexpression)

altered pathways (activated cell survaval, loss of apopototic signals

altered biology
(limitless replication, angiogenesis, tissue invasion)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

cancer treatment options?

A 
surgery
radiotherapy
chemo
hormonal
targeted therapy
adjuvant therapy
palliative care
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

define overall survival

A

length of time that patients are

alive, from either diagnosis or commencing treatmen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

define progression free survival

A

length of time that

patients have disease but it does not get worse

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

define disease free survival

A

length of time after completing

treatment without any signs or symptoms of cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

define response rate

A

percentage of patients whose cancer

shrinks or disappears after treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

traditional diagnosis steps

A

1) site
2) invasion
3) histology
4) differentiation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

traditional primary characteristic of cancer

A

uncontrolled cell division

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

traditional primary cancer treatment

A

chemotherapy - which inhibits DNA replication, disrupts microtubule function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what does tamoxifen do?

A

used for the treatment of both early and advanced estrogen receptor (ER)-positive (ER+) breast cancer

acts as an ER antagonist so that transcription of estrogen-responsive genes is inhibited

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

modern primary characteristics

A

specific mutations drive cell division

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

modern primary treatment

A

targeted therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what is gleevec/imatinib?

A

chemotherapy medication used to treat cancer. Specifically, it is used for chronic myelogenous leukemia (CML)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what is the philadelphia chromosome assoc with and what is it?

A

CML

Specific genetic abnormality in chromosome 22 of leukemia cancer cells

This chromosome is defective and unusually short because of reciprocal translocation of genetic material between chromosome 9 and chromosome 22, and contains a fusion gene called BCR-ABL1. This gene is the ABL1 gene of chromosome 9 juxtaposed onto the BCR gene of chromosome 22, coding for a hybrid protein: a tyrosine kinase signalling protein that is “always on”, causing the cell to divide uncontrollably

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what is HER2?

A

member of human epidermal growth factor receptor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

role of HER2 in cancer?

A

Amplification, also known as the over-expression of the ERBB2 gene, occurs in approximately 15-30% of breast cancers.It is strongly associated with increased disease recurrence and a poor prognosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

what is heceptin/trasruzumab?

A

humanised monoclonal antibody against HER2.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

how doesherceptin/trastuzumab work?

A

Dimerised
HER2 receptors
signal to cells
to proliferate

Herceptin flags cells for
immune-
mediated death
(antibody dependent cellular
cytotoxicity, ADCC

Herceptin blocks downstream
HER2 signalling,
inhibiting proliferation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

what was the response to herceptin?

A

Progression free survival increased from 4.6 to 7.4 months
•
Longer response to treatment, from 6.1 to 9.1 months
•
Increased survival, from 20.3 to 25.1 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

name another anti-her2 therapeutic agent and how is it different

A

pertuzumab

targets a different part of the HER2 receptor.

Can use both pertuzumab and herceptin so they work synergistically.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

what is trastuzumab(herceptin)emtansine?

A

herceptin that is conjugated to emtansine.

Trastuzumab alone stops growth of cancer cells by binding to the HER2/neu receptor. can also bind to EC domain, draw in immune system to kill

whereas emtansine can get takin into cells and broken down emantine is liberated and destroys them by binding to tubulin - disrupting microtubule assembly.

get 3 mechanisms of action in one.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

how is HER2 detected?

A

using IHC (immunohistochemistry) and FISH (fluorescence in situ hybridisation)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

what is lapatinib

A

tyrosine kinase inhibitor which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways.

Can use all 3 together.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
what is anaplastic lymphoma kinase (ALK)?
``` Cell surface receptor with intracellular TK domain • Wild type activation: ligand binding, dimerization, autophosphorylation • Associated with: cell - cycle progression, survival, proliferation, angiogenesis. ```
26
What is EML4-ALK
Its a fusion oncogene get inversion in chr 2 which brings together half of EML4 and half of ALK = fusion gene, constantly active
27
What is EML4-ALK associated with?
found in non-small cell lung cancer
28
what is PF-02341066
A drug used to treat non-small cell lung cancer that has spread to other parts of the body. It is a cMet (tyrosine protein kinase Met) selective tyrosine kinase inhibitor. Also an inhibitor of the ALK tyrosine kinase
29
what does PF-02341066 do?
It is used in patients whose cancer has a mutated (changed) form of the anaplastic lymphoma kinase (ALK) gene or the ROS1 gene. PF-02341066 blocks the proteins made by the mutated ALK genes. Blocking these proteins may stop the growth and spread of cancer cells. PF-02341066 may also prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Also called crizotinib, MET tyrosine kinase inhibitor PF-02341066, and Xalkori
30
what was the ALK therapy used called and what was its response?
crizotinib, 50%
31
better to start with 1st or 2nd gen drug?
trials show, better to start with 2nd gen drug as they are more potent/effective
32
how does drug resistance occur?
1) you've got a mutated cell, forming a tumour. However the tumour is not homogenous, not same clonal expansion of that original cell. There are different cells within that tumour each with their own mutations. 2) when you treat tumour with targeted therapy, you are killing most of the cells in that tumour, but there are some which will be resistant in someway which can go and form a second tumour. Alternativley you afre creating a selection pressure (drug) which kills of most cells, leaving a few behind which can survive.
33
what are the mechanisms of tumour resistance?
1) survival of the fittest 2) sometimes the tumour will develop a secondary mutation which give rise to resistance. 3) ALK amplification 4) activating alternative signalling/pathways 5) upregulation of frug efflux pump p-glycoprotein (MDR1)
34
how can secondary mutation give rise to resistance (ALK-TKI)?
the resistance can hinder the drug binding to the TK, alter kinase conformation, affects binding affinity for ATP of the TK
35
explain ALK amplification
amplification of fusion genes in subset of genes and when tumour reoccurs youi see cells all contain that ALK
36
explain upregulation of efflux pump
upregulation of a pump which can pump the drug out of the cancer cell
37
what is the classic gene involved in upreg of drug efflux pump and what does it code for?
Multi-drug resistance 1 gene (MDR1) codes for p-glycoprotein
38
what drug is used against efflux pump?
can give verapamil (alongside crizotinib) - which inhibits p-glycoprotein
39
what does EGFR stand for?
epidermal growth factor receptor
40
structure of EGFR?
extracellular domain, transmembrane domain, intracellular tyrosine kinase domain
41
EGFR role in cancer?
common mutations in the IC TK domain, which activate the TK domain which then activated downstream signalling pathways which then gives cancerous phenotype
42
drug against EGFR?
EGFR TKI such as gefitinib
43
what drug is used in melanoma and how does it work?
vemurafenib - targets the v600e mutation in BRAF. second gen: trametinib
44
advantages of targeted therapies
Exceptional responses in some patients Increased survival Well tolerated compared to cytotoxic chemotherapy
45
problems w targeted therapies?
``` 1)Most patients lack the molecular changes treatable with current molecular therapies e.g V600E BRAF ≈ 50% (melanoma) HER2 overexpression <30% (breast) HER2 overexpression <20% (gastric) EML4ALK translocation <6% (NSCLC) ``` 2) Clinical trials: must recruit many patients to identify sufficient with the molecular change e.g oGA Trial of Herceptin in gastric cancer: recruited ~4000 patients <600 treated
46
what is basket/bucket trial?
one drug, many tumour types eg ALK inhibitor
47
what is umbrella trial?
one tumour type, treat with lots of drugs ie. lung `cancer
48
what is NCI-MATCH?
National Cancer Institute - Molecular Analysis for Therapy Choice. Trying to find 6000 patients with solid tumours, lymphoma and myelome. DNA seq of 142 key genes. Depending on which mutations are present of those genes, the patient will go into on of 24 arms of clinical trials.
49
more problems with targeted therapies?
1) Most patients lack targets 2) Clinical trial recruitment and design 3) Evolution of resistance ``` 4)Relatively short survival gains - Ceritinib , no improvement wrt chemotherapy - Herceptin, 5 month gain (25 month total) - Pertuzumab , 16 month gain (56 month total) ``` ``` 5)Expensive - Pertuzumab , £16,765 - Nivolumab (melanoma), £5,700/month ```
50
what is early stage breast cancer?
breast cancer which has not spread
51
how you treat early stage breast cancer?
surgery (lumpectomy, mastectomy) adjuvant therapy: radiotherapy, chemotherapy, hormone therapy (ER+ve tamoxifen) need to predict recurrence in patients with LN -ve, ER+ve breast cancer
52
how to predict patients whos cancer will recur
measuring gene expresion using microarrays
53
give name of microarray that predicts recurrence in breast cancer
oncotype Dx
54
what did NICE(2013) conclude the best predictor?
oncotype Dx
55
how does oncotype Dx work?
uses 21 genes | uses qRT-PCR
56
what was the impact of the oncotype Dx
Decreased chemotherapy use Increased confidence in decision making Cost effective in the UK
57
what to do with intermediate patients?
trial assigning individualized options for treatment (TAILORx) findings (sparano et al 2015) foung 16% of patients were lo risk and entered arm A, recieving hormone therapy alone, 98% still alive after 5 years. concluded patients with a low risk repxression profile can be spared chemo and their risk of recurrence within 5 years is less than 2%.
58
traditional method of monitoring disease?
imaging using CT and PET molecular markers: PSA, CA15-3
59
what is metastasis?
when you have a primary tumour, some cells break away and invade the blood circ and lymphatic system. Circulate round going elsewhere to distant sites and form a tumour in new location.
60
circulating tumour cells?
found in absence of signs of metastasis found months/years after resection cell count correlates with prognosis (miller et al 2010)
61
cell free DNA (cfDNA)
some dna is found free floating in blood (short fragments). Unknown reason. sequence primary tumour and normal cells, identify tumour specific genomic variants, blood sample, isolate DNA from plasma, PCR amplification, sequencing and quantitation of tumour-specific mutations indicated tumour burden.
62
advantages of CTC and cFDNA?
More sensitive than imaging techniques Less invasive than biopsy Longitudinal sampling to monitor disease progression and response to treatmen

Personalised Medicine (17 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions